The
company's hard asset value (which excludes the PDL biotechnology business intellectual property) rests
mainly on its holding of cash and equivalents contributed
by PDL (the «Book Value» column shows the assets as they are carried in the
financial statements, and the «Liquidating Value» column shows our estimate of the value of the assets in a liquidation):